Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein That Predicts Tamoxifen Resistance is Identified

05.12.2003


Kimberly Blackwell, M.D.


Researchers at the Duke Comprehensive Cancer Center have identified a protein that breast cancer tumors over-produce when they become resistant to the drug tamoxifen. The researchers said their finding could help them predict which tumors will benefit from tamoxifen -- the front-line drug used to treat operable breast cancer -- and which tumors won’t.

Future studies will be able to determine if tumors that over-produce this protein, called MTA-1, could be treated with a different hormonal therapy following their initial treatment with surgery, chemotherapy and/or radiation, said Kimberly Blackwell, M.D., assistant professor of oncology at the Duke Comprehensive Cancer Center.

Blackwell will present her team’s findings on Dec. 4 at the 26th annual San Antonio Breast Cancer Symposium.



Their latest findings supports last year’s discovery, reported at the same annual meeting, in which Blackwell demonstrated that tamoxifen-resistant tumors actually change their cellular characteristics to become responsive to other types of drugs. Blackwell says that elevated levels of MTA-1 represent one of these cellular changes in tumors that stop responding to tamoxifen.

"MTA-1 is just one of the proteins that plays a role in tamoxifen resistance, but it is one important step toward helping us better target our therapies toward each woman’s particular type of tumor," said Blackwell. "Theoretically, we could biopsy women at the time of diagnosis and select an alternative drug to tamoxifen if their tumors over-express MTA-1."

Furthermore, she said, MTA-1 is known to be a predictor of poor prognosis and the potential for breast cancer metastasis, so that testing for its presence prior to treatment could help them devise more aggressive strategies from the outset.

In years past, tamoxifen was the only option to help prevent breast cancers from recurring in women with estrogen-positive tumors, said Blackwell. But a percentage of women develop resistance to the drug.

To better understand this phenomenon, Blackwell and colleagues developed a strain of mice whose tumors eventually became resistant to tamoxifen. Once tamoxifen resistance was achieved, they conducted a gene array analysis to determine which genes were over-expressed in the new tumor line. They identified 20 different such genes, and found that MTA-1 was a gene that was strongly over-expressed in the tamoxifen-resistant tumors.

To date, scientists have found only a few other genes or proteins over-expressed in tamoxifen-resistant tumors, making the new discovery an important one for determining how a tumor will respond to treatment.

"We have a multitude of hormonally based drugs at our disposal that are designed to treat or prevent breast cancer and its recurrence," said Blackwell. "Our ultimate goal is to test tumors at the time of diagnosis to determine what their molecular signatures are and then to select the best therapy aimed at treating the tumor."

Other authors on the research team, all from Duke, include Mark Dewhirst, Ph.D., Donald McDonnell, Ph.D., Holly Dressman, M.D., Stacey A. Snyder, and Jeffrey R. Marks, Ph.D.

Becky Levine | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7268

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Electrode materials from the microwave oven

19.10.2017 | Materials Sciences

New material for digital memories of the future

19.10.2017 | Materials Sciences

Physics boosts artificial intelligence methods

19.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>